Second NRF2 Degrader Enters Clinical Development: Nutshell Therapeutics' NTS231 Received FDA IND Clearance

SHANGHAI, Sept. 25, 2026 /PRNewswire/ -- Nutshell Therapeutics (Shanghai) Co., Ltd. ("Nutshell Therapeutics"), an innovative biotech company focused on AI-driven allosteric drug discovery, announced FDA IND clearance for NTS231, a covalent allosteric molecular glue degrader of NRF2, to launch clinical development in the United States.

NTS231 is the first NRF2 degrader molecule from China and second globally to enter clinical development. This program represents a significant advancement in efforts to therapeutically target the NRF2 pathway, a key driver of tumor survival and treatment resistance in multiple cancer types.

AI-Driven Discovery of a Novel NRF2-Targeting Molecular Glue

The discovery of NTS231 was powered by Nutshell Therapeutics' proprietary AI-driven allosteric drug discovery platform, ALLOSTAR™, which integrates computer-aided drug design (CADD), medicinal chemistry and cutting-edge experimental techniques.

By leveraging the ALLOSTAR™ platform, Nutshell Therapeutics successfully identified NTS231 as a highly potent and selective novel small molecule that covalently binds to KEAP1 and induces the degradation of NRF2. Mechanistically, NTS231 irreversibly links to the Cys151 residue of KEAP1 and stabilizes the KEAP1 structural conformation conducive to CUL3 interaction as well as the assembly of functional KEAP1–CUL3 E3-ligase complex, thereby driving NRF2 degradation, suppressing NRF2 signaling pathway, and inhibiting cancer cell viability. The team accomplished IND approval within 24 months from target nomination, highlighting AI-enabled acceleration of drug discovery.

Robust Preclinical Antitumor Activity and Desirable Safety Profile

In preclinical studies, NTS231 exhibits non-inferior in vitro activities to VVD-130037[1], a clinical-stage compound under the same targeting mechanism, while possessing superior pharmacokinetic properties. Across multiple cell-derived xenograft (CDX) and patient-derived xenograft (PDX) models harboring diverse NRF2/KEAP1/CUL3 mutations or NRF2 hyperactivation, NTS231 has demonstrated dose-dependent antitumor efficacy as a single agent in a range of solid tumors, including lung squamous cell carcinoma (LUSC), lung adenocarcinoma (LUAD), esophageal squamous cell carcinoma (ESCC), and head and neck squamous cell carcinoma (HNSCC).

NTS231 has also demonstrated the potential for combination therapies. Synergistic antitumor effects were observed when combining NTS231 with chemotherapy, targeted therapies, and antibody-drug conjugates (ADCs). Notably, in chemotherapy-resistant LUSC PDX models harboring KEAP1 and other mutations, the combination of NTS231 and paclitaxel significantly enhanced tumor growth inhibition relative to single agents; in a proof-of-concept CDX model of NFE2L2-amplified LUAD, combined treatment with NTS231 and a TROP2 ADC dramatically improved efficacy and led to tumor regression, accompanied by decreased expression of NRF2-regulated efflux transporters, which might sensitize tumors to ADC payloads and mitigate resistance.

In the 28-day Good Laboratory Practice (GLP) toxicology studies conducted in rats and dogs, NTS231 demonstrated a favorable safety profile and a wide safety margin. These findings provide important preclinical support for the continued clinical development of NTS231.

Targeting a Significant Unmet Need in NRF2-Driven Cancers

Constitutive activation of NRF2 has been observed in many human cancers as a result of genetic alterations in the NRF2-encoding gene NFE2L2 and its regulatory genes KEAP1 and CUL3. Approximately 12% of cancer patients profiled in The Cancer Genome Atlas (TCGA) database carry mutations in at least one of the three genes NFE2L2, KEAP1 or CUL3, particularly prevalent in >30% LUSC and >20% LUAD. Preliminary estimates indicate over 1.5 million annual new cancer cases worldwide harbor NRF2/KEAP1/CUL3 alterations or other aberrant NRF2 pathway activation.[2]

This patient population is largely ineligible for most targeted therapies, given that NRF2/KEAP1/CUL3 alterations are mutually exclusive with EGFR, ALK, ROS1, and BRAF genetic lesions. Immunotherapy likewise yields limited efficacy, since such mutations are strongly associated with an immunologically cold tumor microenvironment (TME) that leads to therapeutic resistance. Constant activation of the NRF2 pathway resulting from mutations in NRF2, KEAP1 or CUL3 can also confer resistance to standard chemotherapy. Collectively, these factors underscore the substantial unmet medical need for effective therapies targeting NRF2-driven tumor biology.

By directly targeting the KEAP1–NRF2 regulatory axis, NTS231 has the potential to provide a new therapeutic approach for patients with NRF2, KEAP1, or CUL3 mutations, as well as tumors characterized by NRF2 pathway hyperactivation.

About Nutshell Therapeutics

Nutshell Therapeutics (Shanghai) Co., Ltd. is an innovative biotechnology company leveraging artificial intelligence and allosteric drug discovery to develop small-molecule therapeutics against historically challenging and "undruggable" targets. Founded by Professor Zhang Jian, a recognized pioneer in the field of allosteric drug discovery, Nutshell Therapeutics has built an integrated R&D team with expertise spanning artificial intelligence, medicinal chemistry, pharmacology, toxicology, and clinical development. The company has focused on small-molecule drug discovery based on protein conformational regulation and has developed an integrated discovery platform combining computational and experimental approaches. Nutshell Therapeutics operates a 1,500-square-meter R&D center in Shanghai integrating computational and experimental research capabilities. The company has raised tens of millions of U.S. dollars from multiple established venture capital investors.

SOURCE Nutshell Therapeutics (Shanghai) Co., Ltd.

Share this article

Including 2027's best colleges, a partnership for Royal Caribbean and Sandals Resorts, and ALDI's first-ever ready-made meals.

NEW YORK, Sept. 25, 2026 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories from the week that shouldn't be missed.

The list below includes the headline (with a link to the full text) and an excerpt from each story. Click on the press release headlines to access accompanying multimedia assets that are available for download.

- MIT Claims No. 1 Spot in U.S. News 2027 Best Colleges Rankings

The 2027 edition introduces significant methodology changes designed to address growing public concerns regarding higher education affordability and long-term value. Chief among these is the new Earnings by Major ranking factor, which evaluates graduate earnings four years post-graduation using data from the U.S. Department of Education's College Scorecard.

- Royal Caribbean Group and Sandals Resorts Announce Landmark Partnership to Accelerate Their Leading Vacation Experiences

United in a shared history in the Caribbean and connected by a love for their communities, the companies will offer travelers an unparalleled collection of cruise, private destination and resort experiences, serving guests across more vacation occasions and establishing their undisputed leadership in Caribbean vacations.

- Casio to Release Limited-Edition Timepiece Celebrating MR-G 30th Anniversary.

To commemorate the 30 years since the debut of MR-G in 1996, Casio drew from metal leaf, embodying tradition and innovation. The design expresses a strength that transcends time through the theme of haruka (eternity). Metal leaf artist Hiroto Rakusho created an original artwork, which together with the timepiece design brings the world of haruka to life.

- Basecamp Research raises $140M to advance AI-designed therapeutics

Basecamp's ambition is to develop cures for diseases that remain incurable by designing medicines that reprogram the body to repair itself. The company combines frontier AI models trained on proprietary biological data with technology for writing DNA sequences into cells.

- Georgia Power agreement with Google to provide approximately $900 million in projected benefits for customers and advance nuclear energy in Georgia

Under the agreement, which is subject to approval by the Georgia Public Service Commission (PSC), Google will support uprates on Georgia Power's owned portion of the nuclear units at Plants Vogtle and Hatch that will allow the facilities to add approximately 96 megawatts of new capacity to the electric grid to serve Georgia Power customers.

- Handshake launches first AI Skills Studio to prepare job seekers for the AI economy

AI Skills Studio offers personalized, project-based "missions" that take between 10 and 45 minutes to complete. Learners work in the AI tools used by practitioners, with an AI Skills Instructor providing guidance and feedback along the way. Every mission ends with something tangible the learner has built, from an automated workflow to a working piece of software.

- ALDI Launches First-Ever Collection of Ready-Made Meals

The seven new ready-made meals include five single-serve options and two family-size meals featuring protein-forward, filling dishes, comforting classics and globally inspired recipes. Single-serve meals under $8 and family-size offerings under $15 give shoppers affordable options with restaurant-quality flavor and texture at the center of each recipe. The collection begins rolling out in early October, available nationwide by January 2027.

- Fat Bear Week 2026 Brings the World Together to Celebrate Wildlife and Conservation

The annual competition puts the remarkable brown bears of Brooks River in the global spotlight, inviting viewers to follow their journeys, discover their stories, and celebrate the strength, adaptability, and resilience of life in the wild.

- New IBM CHRO Study: AI Puts Critical Thinking at the Center of Workforce Priorities

While 71% of Chief Human Resource Officers (CHROs) identify the ability to supervise, validate and override AI outputs as the workforce's most essential skill, only 29% of employees rank judgment as important.

- Teal Health Raises $22 Million Series A to Expand Access to the Most Accurate FDA-Authorized At-Home HPV Cervical Cancer Screening

The financing brings Teal Health's total funding to $45 million. It arrives at a critical moment where nearly one in three U.S. women isn't up to date on screening, largely due to physician shortages causing limited appointment availability and therefore making the traditional in-office screening difficult to access.

- MONOPOLY® Returns to McDonald's: Score Bigger Prizes, More Rewards and Easier Gameplay

Starting Oct. 6 for a limited time, fans can play the game they know and love with a simplified experience and one-of-a-kind prize list. With all the pieces in your hands, fans will now have just one way to peel, with all gameplay done in the app. Peel the game pieces, then scan in the app to cash in instant-win food or loyalty points or play for the biggest prizes.

- Cognex to Acquire RealSense, Expanding Machine Vision Leadership into High-Growth Robotic Perception Market

"Combined with Cognex's machine vision expertise and global reach, RealSense positions us to offer a full-stack visual intelligence platform, spanning industrial ID, 2D and 3D machine vision measurement to 3D depth perception and robotic navigation, built to serve the full spectrum of Physical AI," said Matt Moschner, President and Chief Executive Officer of Cognex.

- Athletic Brewing Company and Graza Cook Up Non-Alcoholic Collaboration Brew, 'Cold Off The Press'

A classic pils with floral, herbal, and lemon aromas and a remarkably clean, dry finish, the brewing process for Cold Off The Press began with extra virgin olive oil, which nourishes the yeast that helps shape the brew.

Read more of the latest releases from PR Newswire.

Do you have a press release to distribute? Sign up with PR Newswire to share your story with the audiences who matter most.

Helping Journalists Stay Up to Date on Industry News

These are just a few of the recent press releases that consumers and the media should know about. To be notified of releases relevant to their coverage area, journalists can set up a custom newsfeed with PR Newswire for Journalists.

Once they're signed up, reporters, bloggers, and freelancers have access to the following free features:

- Customization: Users can create customized newsfeeds that will deliver relevant news right to their inbox. Newsfeed results can be targeted by keywords, industry, subject, geography, and more.

- Photos and Videos: Thousands of multimedia assets are available to download and include in a journalist or blogger's next story.

- Subject Matter Experts: Journalists will have access to ProfNet, a database of industry experts to connect with as sources or for quotes in their articles.

- Related Resources: Our journalist- and blogger-focused blog, Beyond Bylines, features regular media news roundups, writing tips, upcoming events, and more.

About PR Newswire

PR Newswire is the industry's leading press release distribution partner with an unparalleled global reach of more than 500,000 newsrooms, websites, direct feeds, journalists and influencers and is available in more than 170 countries and 40 languages. From our innovative AI-powered PR Newswire Amplify™ platform, award-winning Content Services offerings, integrated media newsroom and microsite products, Investor Relations suite of services, paid placement and social sharing tools, PR Newswire has a comprehensive Multichannel Amplification™ catalogue of solutions to solve the modern-day challenges PR and communications teams face. For more than 70 years, PR Newswire has been the preferred destination worldwide for brands to share their most important news stories.

For questions, contact the team at [email protected].

SOURCE PR Newswire

Share this article

DELRAY BEACH, Fla., Sept. 25, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Aseptic Packaging Market is projected to reach USD 123.76 billion in 2031 from USD 87.87 billion in 2026, at a CAGR of 7.09% from 2026 to 2031.

Browse 370 market data Tables and 70 Figures spread through 300 Pages and in-depth TOC on "Aseptic Packaging Market - Global Forecast to 2031"

Aseptic Packaging Market Size & Forecast:

- Market Size Available for Years: 2022-2031

- 2026 Market Size: USD 87.87 billion

- 2031 Projected Market Size: USD 123.76 billion

- CAGR (2026-2031): 7.09%

Aseptic Packaging Market Trends & Insights:

- The surging demand for aseptic packaging is fueled by the rise of e-commerce and home delivery networks that require lightweight, leak-proof options capable of withstanding long-distance shipping without spoiling

- Asia Pacific accounted for a significant share of 36.84% in 2025.

- By material, the plastic segment accounted for the largest share of 38.75% in 2025.

- By type, the vial, ampoules and prefillable syringes segment is projected to register the highest CAGR of 8.48% during the period.

- By application, the beverages segment accounted for the largest share of 53.75% in 2025.

- Amcor plc (Switzerland), Mondi plc (UK), Smurfit Westrock plc (Ireland), TOPPAN Holdings Inc. (Japan), and Graphic Packaging Holding Company (US) were identified as key players aseptic packaging market (global), given their strong market share and product footprint.

- SIG Group AG (Switzerland), UFlex Limited (India), and Elopak ASA (Norway) have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas, underscoring their potential as emerging market leaders.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=785

Aseptic packaging is a specialized manufacturing method where a sterile product is filled and sealed inside a pre-sterilized packaging material under an entirely sterile environment. This process prevents microbial recontamination, allowing highly perishable foods, beverages, and pharmaceuticals to be transported and stored at room temperature for extended periods without requiring artificial preservatives or continuous refrigeration.

By material, the paper & paperboard segment is expected to account for the fastest CAGR during the forecasted period.

Over the forecast period, the Paper & Paperboard category is predicted to exhibit the fastest compound annual growth rate (CAGR) in the aseptic packaging industry. The strong growth of this sector can be attributed to the global movement towards more sustainable, circular-economy packaging methods that minimize the use of disposable plastic. Paperboard is the basis for the modern aseptic carton design as it provides the necessary strength while keeping the renewable nature of the product. The growing requirements of environmental legislation in various parts of the world encourage manufacturers to invest in R&D for the development of eco-friendly alternatives to currently used plastic products, such as novel bio-derived paper forms. In addition, the modern consumer is becoming more eco-conscious and increasingly prefers brands that promote sustainability.

Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=785

By type, the vials, ampoules, and prefillable syringes segment is expected to account for the fastest CAGR during the forecasted period.

The vials, ampoules, and prefillable syringes segment within aseptic packaging is expected to register the highest growth rate in the coming years. This fast-paced growth can be attributed to the increasing development of biological drugs and their unprecedented demand in the market. As compared to traditional small-molecule drugs, these liquid formulations are more susceptible to degradation and chemical interactions; therefore, perfect sterility is paramount, which can only be achieved using specialized polymer syringes and high-grade glass vials. Moreover, the healthcare sector is heavily leaning towards the use of prefillable syringes to avoid medication errors, as well as eliminate drug wastage. With the expansion of healthcare networks and regulating authorities implementing stricter regulations, pharmaceutical companies have begun using mechanized aseptic filling machines and automation in this domain.

By application, the pharmaceuticals segment is expected to account for the fastest CAGR during the forecasted period.

The pharmaceuticals segment is expected to witness the highest compound annual growth rate (CAGR) in the market for aseptic packaging in the coming years. This tremendous market growth can be attributed to the global upsurge of biopharmaceutical production, including advanced vaccines, complex cellular therapies, monoclonal antibodies, and biosimilars. These advanced liquid medications are very sensitive to environmental conditions and thermal degradation, making standard terminal heat sterilization impossible. Aseptic operation serves as the only way to fill and seal these products while preserving their active chemical structures and ensuring absolute sterility. Also, the new stringent regulations on sterile drug manufacturing force pharmaceutical firms to streamline their supply chains. The increasing clinical adoption of ready-to-use drug delivery systems, such as prefilled syringes and sterile single-dose containers, further strengthens pharmaceuticals as the most rapidly expanding application in the global market.

Asia Pacific is expected to account for the fastest CAGR during the forecast period.

The growth of the aseptic packaging industry in Asia Pacific is expected to be very fast in terms of CAGR in the forecast period. This growth can be credited to fast growth of the economy, increase in disposable income, and high rate of growth of population in many developing countries. With millions of consumers moving to cities and adopting a fast lifestyle, use of packaged dairy goods, RTD beverages, and processed food is growing like never before. At the same time, the boom in the healthcare system and local biopharmaceutical manufacture is increasing the demand for sterile pharmaceutical packaging. Besides, international companies are investing in local production to take advantage of much cheaper production processes and the increasing demand.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=785

Key Players

The major aseptic packaging companies such as Amcor plc (Switzerland), Mondi plc (UK), Smurfit Westrock plc (Ireland), TOPPAN Holdings Inc. (Japan), Graphic Packaging Holding Company (US), Nippon Paper Industries Co., Ltd. (Japan), Dai Nippon Printing Co., Ltd. (DNP) (Japan), Huhtamäki Oyj (Finland), Stora Enso Oyj (Finland), and Tetra Pak International S.A. (Switzerland). Product launches, partnerships, acquisitions, and expansions are some of the major strategies adopted by these key players to enhance their positions in the aseptic packaging market.

Investment and Funding

Investment in the aseptic packaging market is increasingly focused on expanding sterile manufacturing capacity, improving cleanroom automation, and strengthening high-barrier material processing capabilities. Manufacturer disclosures indicate that capital deployment has been directed toward factory expansion, specialized blow-molding and carton-forming equipment, cleanroom robotic systems, computer-controlled filling lines, and integrated material-lamination operations. In recent financial disclosures, Amcor plc announced an expansion of its high-barrier flexible and rigid packaging operations, together with upgrades to its cleanroom automation infrastructure and the integration of advanced robotic handling systems to improve filling line throughput and maintain pristine sterile integrity. During the same fiscal period, Mondi plc reported that its targeted investment in precision co-extrusion and high-speed laminating lines directly increased internal material production capacity, supporting the commercial launch of next-generation, fiber-based liquid packaging systems serving cartons, pouches, and bag-in-box barrier formats Mondi Group Website. Furthermore, Graphic Packaging Holding Company has described major capital investments in additional production facilities, specialist carton-forming machinery, high-definition printing infrastructure, and customized digital layout software to support rising retail sales and increasingly complex multi-layer food and beverage structural barrier requirements Graphic Packaging Website. These global developments strongly suggest that capital investment is moving toward highly scalable, technology-enabled aseptic manufacturing models rather than conventional, non-sterile packaging fabrication capacity alone. The main structural areas attracting funding include automated cleanroom roll-forming, prefabricated barrier cartons, smart packaging integration, advanced materials R&D, and inline sterile processing mechanisms. Packaging manufacturers equipped with modern cleanroom production facilities, specialized sterilization hardware, automated digital workflows, and the ability to supply both rigid and flexible high-barrier containers seamlessly are demonstrably better positioned to attract strategic corporate investment and expand their active customer base. This dynamic financing environment is directly supported by the growing market adoption of preservative-free "clean-label" formulations, biological pharmaceutical products, single-serve convenience foods, and ambient distribution processes that collectively emphasize longer shelf life, lower transport costs, and total elimination of cold-chain dependencies.

Global Leaders Call for Scalable Women's Health Models to Close $1 Trillion Health Gap at Burjeel Holdings' Roundtable in New York

Roundtable held during UN General Assembly week examined how investment, technology, and new models of care can close the global women's health gap

NEW YORK, Sept. 25, 2026 /PRNewswire/ -- Global leaders from healthcare, investment, philanthropy, and government called for greater investment in scalable, integrated models of women's healthcare at "The $1 Trillion Case for Women's Health," a high-level roundtable convened by Burjeel Holdings, a leading super-specialty healthcare services provider in the GCC.

Held on the sidelines of the 81st United Nations General Assembly (UNGA) in New York, the discussion focused on the economic and clinical impact of the global women's health gap, which the World Economic Forum estimates could exceed $1 trillion annually by 2040 if left unaddressed.

The roundtable, opened with a virtual address from HRH Ambassador Reema Bandar Al-Saud, Ambassador of the Kingdom of Saudi Arabia to the United States, speaking about the need to take a more comprehensive approach to women's health.

"It begins with knowledge and prevention," said Princess Reema in her video address. "It begins with creating an environment where women feel comfortable speaking about their health and asking for the care they need. But today, that conversation has to go much further. We have to invest in women everywhere. Women's physical and mental health and overall well-being are interconnected, and our approach to care has to be, too. No nation can ask half of its people to contribute to its future and then leave their healthcare to chance."

Dr. Shamsheer Vayalil, Chairman, and CEO of Burjeel Holdings, continued the discussion with 23 leaders spanning health systems, investment, philanthropy, and multilateral organizations. He pointed out how Burjeel Holdings' clinical experience serves as an example of targeted investment in women's healthcare as a scalable action, already improving the future of women, evidenced by the decline in cervical cancer cases at Burjeel Cancer Institute in the UAE over the past two years.

The Group also previewed collaborative initiatives under development in Saudi Arabia, including an integrated model for women's health delivery that could be adapted for other markets, including across Africa and the wider Global South.

"Women's health has been under-researched, underfunded, and too often treated as episodic rather than lifelong," said Dr. Shamsheer Vayalil during his opening remarks. "Prevention is key, alongside diagnostics, cardiovascular health, cancer, reproductive health, menopause and midlife care, and so much more. Any model implemented needs to be evidence-based, culturally relevant, with trusted, measurable success. Only then will progress be seen."

Ms. Khadija Rejto, Chair of Global Health at the Atria Research and Global health Institute emphasized this point, sharing, "Investors have long treated women's health as a niche despite it being one of the fastest growing sectors in the world."

As conversation continued, participants discussed three critical requirements for closing the women's health gap: a sustained investment in women's health systems, broader adoption of technology across care delivery, and new models of care with a demonstrated record of results.

About Burjeel Holdings

Founded in 2007, Burjeel Holdings is a leading super-specialty healthcare services provider in the UAE and Oman, and it operates a growing specialized healthcare segment in Saudi Arabia. The Group operates an integrated and multi-brand healthcare ecosystem across primary, secondary, tertiary, and quaternary medical care, ensuring complex care delivery to patients across all socioeconomic groups. The network comprises 94 assets across the UAE, Oman, and Saudi Arabia, including 20 hospitals, 44 medical centers and physiotherapy centers, 16 pharmacies, and 14 other allied services. Burjeel Holdings' brands include Burjeel, Medeor, LLH, Lifecare, Alkalma, and Tajmeel.

SOURCE Burjeel Holdings

Share this article

- New results suggest earlier treatment may increase the likelihood of long-term remission

- Study adds to Johnson & Johnson's overwhelming body of evidence supporting its innovative multiple myeloma therapies in second line, where earlier intervention may increase long-term remission and disease control

RARITAN, N.J., Sept. 25, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, announced today new long-term follow-up data from the initial subgroup of cohort A in the Phase 2 CARTITUDE-2 study (N=20) showing that 50% of patients (10/20) in early line relapsed or refractory multiple myeloma (RRMM) who were treated with a single infusion of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) remained alive and progression-free for at least five years without maintenance therapy.1 These results build on the durable, treatment-free remissions observed in the CARTITUDE-1 study, which evaluated patients in later lines of therapy, and reinforce that earlier treatment with CARVYKTI® may increase long-term remission and disease control. Together, these findings add to the emerging evidence suggesting that CARVYKTI® may have curative potential in some patients.

Findings were presented at the International Myeloma Society (IMS) Annual Meeting (Abstract #PA-288).

Expert and company perspectives on earlier treatment-free remissions with CARVYKTI®

"Five years ago, treatment-free remissions of this duration were difficult to imagine for many patients with relapsed or refractory multiple myeloma," said Niels van de Donk, M.D., Ph.D., Professor of Hematology, University Medical Center, Amsterdam, the Netherlands.* "These new CARVYKTI findings provide additional evidence that when highly effective, established therapies are used earlier in the disease course, more patients may have the opportunity to achieve deep, durable remissions and long-term disease control without maintenance."

"These results add to the growing body of evidence suggesting that CARVYKTI may have curative potential for some patients, and reinforce the value of bringing highly effective therapies to patients earlier in their treatment journey," said Yusri Elsayed, M.D., M.H.Sc., Ph.D., Global Therapeutic Area Head, Oncology, Johnson & Johnson. "As we continue to advance a portfolio of complementary and combinable therapies, these findings reinforce our commitment to pursuing curative approaches and redefining what patients can expect from multiple myeloma treatment."

Phase 2 CARTITUDE-2 study build on previous findings

CARTITUDE-2 cohort A (N=20) enrolled patients with RRMM who had received one to three prior lines of therapy, were exposed to a proteasome inhibitor, and were refractory to lenalidomide.1 The primary endpoint was minimal residual disease (MRD) negativity.1 Patients from initial cohort A were followed to assess long-term outcomes following a single CARVYKTI® infusion without maintenance therapy.1

At a median follow-up of 60.7 months:

- Half of the patients (n=10, 50%) remained alive and progression-free at five years

- The five-year overall survival rate was 69.2%

- Median progression-free survival was 60.5 months

- Patients received a single CARVYKTI® infusion without maintenance therapy

At five years, MRD was assessed by bone marrow in three patients and was not required per protocol.1 All three patients were MRD-negative at the deepest level tested (10-6), indicating no detectable disease using highly sensitive testing methods.1

Long-term remissions were observed even among patients with high-risk disease features.1 Of the 10 patients who remained alive and progression-free at five years, five had at least one high-risk cytogenetic abnormality, including four patients with two or more high-risk features.1

The safety profile observed with longer follow-up was consistent with the known safety profile of CARVYKTI®, with no new CAR T-cell-related neurotoxicity reported.1 Since the previous analysis, one patient developed a new hematologic malignancy (acute myeloid leukemia) and two deaths occurred due to progressive disease and new cancer.1

About CARTITUDE-2

CARTITUDE-2 (NCT04133636) is an ongoing, multicohort Phase 2 study evaluating the efficacy and safety of ciltacabtagene autoleucel (CARVYKTI®) in patients in different clinical settings, including patients with one to three prior lines of therapy, and continues to generate long-term follow-up data on depth and durability of response. CARTITUDE-2 findings have been presented at major medical congresses, including the International Myeloma Society (IMS) Annual Meeting, and contribute to the growing body of evidence supporting earlier use of CARVYKTI® in multiple myeloma.

About multiple myeloma 

Multiple myeloma is a complex blood cancer that affects a type of white blood cell called plasma cells, which are found in the bone marrow.2 In multiple myeloma, these plasma cells proliferate and spread rapidly and replace normal cells in the bone marrow with tumors.3 Multiple myeloma is the third most common blood cancer worldwide.4 More than 180,000 new cases of multiple myeloma are diagnosed globally each year.5 People living with multiple myeloma have a 5-year survival rate of 59.8%.6 While some people diagnosed with multiple myeloma initially have no symptoms, most patients are diagnosed due to symptoms that can include bone fracture or pain, low red blood cell counts, tiredness, high calcium levels and kidney problems or infections.7,8 In recent years, potential overall survival has improved from years to decades for some patients, with effective treatment options now available across every stage and line of therapy.9

About Johnson & Johnson's multiple myeloma portfolio 

Johnson & Johnson is a global leader in multiple myeloma therapies, with a broad and differentiated portfolio designed to address the complexity and heterogeneity of the disease. Our portfolio spans multiple mechanisms of action, targets and treatment modalities, including CD38-directed therapies, BCMA- and GPRC5D-targeting bispecific antibodies, and cellular therapies. 

Over the past decade, Johnson & Johnson therapies have helped extend survival for patients with multiple myeloma. With the right medicines, used as early as possible, combined and sequenced for the best results, Johnson & Johnson is expanding treatment options to match the right therapy to the right patient at the right stage of disease and drive deeper and more durable responses.

Through ongoing research and a robust clinical program, Johnson & Johnson is committed to transforming multiple myeloma into a more manageable condition that is no longer treated to progression but has the potential to, ultimately, be cured.

About CARVYKTI®

CARVYKTI® (cilta-cel) received U.S. Food and Drug Administration approval in February 2022 for the treatment of adults with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.10

In April 2024, CARVYKTI® was approved in the U.S. for treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor, an immunomodulatory agent, and who are refractory to lenalidomide, following a unanimous (11 to 0) FDA Oncologic Drugs Advisory Committee (ODAC) recommendation in support of this new indication. In April 2024, the European Medicines Agency (EMA) approved a Type II variation for CARVYKTI® for the treatment of adults with relapsed and refractory multiple myeloma who have received at least one prior therapy, including an immunomodulatory agent and a proteasome inhibitor, have demonstrated disease progression on the last therapy, and are refractory to lenalidomide. In September 2022, Japan's Ministry of Health, Labour and Welfare (MHLW) approved CARVYKTI® for the treatment of adults with relapsed or refractory multiple myeloma in patients that have no history of CAR-positive T cell infusion therapy targeting BCMA and who have received three or more lines of therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 monoclonal antibody, and in whom multiple myeloma has not responded to or has relapsed following the most recent therapy. In July 2026, CARVYKTI® obtained a label expansion in Japan, allowing its use in patients with relapsed or refractory multiple myeloma who have received at least on prior therapy.

CARVYKTI® is a BCMA-directed, autologous T-cell immunotherapy, which involves reprogramming a patient's own T-cells with a transgene encoding chimeric antigen receptor (CAR) that directs the CAR-positive T cells to eliminate cells that express BCMA. BCMA is primarily expressed on the surface of malignant multiple myeloma B-lineage cells, as well as late-stage B cells and plasma cells. The CARVYKTI® CAR protein features two BCMA-targeting single domains designed to confer high avidity against human BCMA. Upon binding to BCMA-expressing cells, the CAR promotes T-cell activation, expansion, and elimination of target cells. CARVYKTI® is available in 17 markets worldwide and has been used to treat more than 13,000 patients globally.

In December 2017, Janssen Biotech, Inc., a Johnson & Johnson company, entered into an exclusive worldwide license and collaboration agreement with Legend Biotech USA, Inc. to develop and commercialize CARVYKTI®.

For more information, visit www.CARVYKTI.com.

CARVYKTI® Important Safety Information

WARNING: CYTOKINE RELEASE SYNDROME, NEUROLOGIC TOXICITIES, HLH/MAS, PROLONGED and RECURRENT CYTOPENIA, and SECONDARY HEMATOLOGICAL MALIGNANCIES Cytokine Release Syndrome (CRS), including fatal or life-threatening reactions, occurred in patients following treatment with CARVYKTI®. Do not administer CARVYKTI® to patients with active infection or inflammatory disorders.

Hearty, home‑style recipes bring warmth and satisfaction to the fall season.

DENVER, Sept. 25, 2026 /PRNewswire/ -- As temperatures drop and comfort‑food cravings rise, beef takes center stage as the ultimate ingredient for warm, satisfying autumn meals. This season, the Beef. It's What's For Dinner. brand, funded by beef farmers and ranchers, is highlighting three classic dishes that deliver slow‑cooked richness, homestyle nostalgia and the kind of hearty flavor that defines fall.

Great for weeknight dinners, this Mississippi Pot Roast is a slow‑cooked favorite featuring tender beef, savory seasonings and rich juices. Ideal for crisp fall days when you want a set‑it‑and‑forget‑it meal that fills the house with comforting aromas – just plate it over couscous, mashed potatoes or noodles and it's ready to go.

If you're looking for something extra comforting during a cozy weekend at home, you can't go wrong with Classic Country-Fried Steaks & Gravy. Crispy, golden country‑fried steaks smothered in creamy gravy – it's a nostalgic, stick‑to‑your‑ribs dish that brings Southern comfort to any autumn table.

Feeding a crowd during fall gatherings doesn't have to be intimidating with this Beef Pot Pie. A hearty pot pie packed with tender beef and vegetables under a flaky, golden crust – this is a great example of beef's versatility during those chilly evenings with family and friends.

For more comforting dishes to make part of your seasonal traditions, visit BeefItsWhatsForDinner.com.

About the Beef Checkoff

The Beef Checkoff Program was established as part of the 1985 Farm Bill. The Checkoff assesses $1 per head on the sale of live domestic and imported cattle, in addition to a comparable assessment on imported beef and beef products. States may retain up to 50 cents on the dollar and forward the other 50 cents per head to the Cattlemen's Beef Promotion and Research Board, which administers the national checkoff program, subject to USDA approval.

About NCBA, a Contractor to the Beef Checkoff

The National Cattlemen's Beef Association (NCBA) is a contractor to the Beef Checkoff Program. The Beef Checkoff Program is administered by the Cattlemen's Beef Board, with oversight provided by the U.S. Department of Agriculture.

Media Contact: Hailey Thayn, 303-850-3392, [email protected]

SOURCE National Cattlemen's Beef Association

Share this article

AUSTIN, Texas and HONG KONG, Sept. 25, 2026 /PRNewswire/ -- At the FOW Asia Pacific Awards in Hong Kong last night, Eventus, a leading provider of comprehensive, at-scale trade surveillance and financial risk solutions, won the award for Market Surveillance Solution of the Year for its Validus platform. Earlier this year, Eventus won the same category for the fourth time in the FOW International Awards.

The win follows the firm's recognitions in July as Best Trade Surveillance Solution in the Capital Markets Technology Awards APAC and Trade Surveillance Product of the Year in the global Risk Technology Awards.

The FOW Asia Pacific Awards, hosted by Futures & Options World (FOW), recognize outstanding performance and innovation for firms and individuals in the Asian derivatives industry. A specialist panel of independent industry experts with relevant subject matter expertise from across the Asia-Pacific (APAC) region select the winners in each category.

Eventus CEO Cameron Routh said: "APAC continues to be a cornerstone of our strategy and strong growth driver, and clients appreciate our collaborative approach, ensuring that Validus reflects the changing rules in the various jurisdictions in which they operate. It's always a great honor to earn an award from FOW and the independent judges who understand what we do."

More than 50% of new global Eventus clients have a presence in APAC, and the firm has 30 active clients in the region, ranging from brokerage firms, to proprietary trading firms and digital asset marketplaces.

Eventus, which has now won more than 50 awards and honors since 2018, has earned 17 honors for the APAC region alone.

About Eventus

Eventus provides state-of-the-art, at-scale trade surveillance software across all lines of defense. Its powerful, award-winning Validus platform is easy to deploy, customize and operate across equities, options, futures, foreign exchange (FX), fixed income, digital asset and prediction/information markets. Validus is proven in the most complex, high-volume, and real time environments of Eventus' rapidly growing client base, including tier-1 banks, broker-dealers, futures commission merchants (FCMs), proprietary trading groups, market centers, buy-side institutions, energy and commodity trading firms, and regulators. Clients rely on the platform, coupled with the firm's responsive support and product development, to overcome their most pressing trade surveillance regulatory challenges. For more, visit www.eventus.com.

SOURCE Eventus

Share this article

Ault & Company Beneficially Owns Approximately 62% of Hyperscale Data and Believe a Significant Disconnect Exists Between Hyperscale Data's Market Capitalization and the Value of Its Assets

LAS VEGAS, Sept. 25, 2026 /PRNewswire/ -- Ault & Company, Inc. ("Ault & Company"), a private holding company controlled by Milton "Todd" Ault III, today announced that Ault & Company has invested $55 million of capital directly into Hyperscale Data, Inc., an NYSE American listed company ("Hyperscale Data"), through the purchase of convertible preferred stock. Such figure doesn't include funds expended by Ault & Company or any of its affiliates in purchasing Hyperscale Data common stock in open market purchases.

Ault & Company and its affiliates currently beneficially own approximately 62% of Hyperscale Data. For further details on Ault & Company's ownership of Hyperscale Data, please reference the Schedule 13D/A Amendment No. 19, filed with the U.S. Securities and Exchange Commission on September 15, 2026 by Ault & Company and its affiliates.

Ault & Company believes there is an extraordinary disconnect between Hyperscale Data's current public market valuation and the value of the assets and businesses owned by the Hyperscale Data.

Ault & Company believes the following Hyperscale Data assets and opportunities support its long-term investment thesis:

Michigan AI data center. Hyperscale Data has reported that it has invested more than $70 million into the Michigan facility owned and operated by its wholly owned subsidiary, Alliance Cloud Services, LLC ("ACS"). ACS has executed a master services agreement ("MSA") for an initial 20 megawatts ("MW") of critical artificial intelligence ("AI") compute capacity. The customer has the right to expand the deployment to a total of 52 MW.

Long-term contract potential. Hyperscale Data expects revenue from the initial 20 MW deployment to exceed $1.2 billion if the MSA remains in effect for its maximum 20-year term. If the customer exercises its expansion right and the additional capacity remains contracted for the applicable maximum term, total potential contract revenue could exceed $3.0 billion. The contemplated 52 MW deployment could represent less than 20% of the approximately 340 MW of total potential capacity that ACS believes can be ultimately available. Hyperscale Data has advised that the development of any capacity beyond the initial 20 MW covered by the MSA is subject to financing, regulatory approvals, engineering, utility agreements, infrastructure availability, customer demand and other conditions. There can be no assurance that additional capacity will be developed, financed, contracted or placed into service.

Potential value of the Michigan campus. Hyperscale Data management has stated that it presently believes the Michigan campus could support a valuation of approximately $750 million to $1.25 billion. Management of Hyperscale Data has set $750 million as the minimum valuation at which it presently believes a sale would merit serious consideration. The range is management's assessment, not an independent appraisal or an assurance that a transaction could occur at either amount.

Reported asset base. Hyperscale Data reported approximately $360 million of total assets as of June 30, 2026, reflecting its Michigan investment, operating businesses and other holdings.

Operating businesses and strategic assets. Hyperscale Data reported $34.8 million of consolidated revenue for the quarter ended June 30, 2026. Its interests include defense and aerospace, crane rental, hotels, commercial lending, blockchain technology and software, in addition to its Michigan AI data center.

Bitcoin and cash. As of September 13, 2026, Hyperscale Data reported approximately $51 million of Bitcoin, cash and restricted cash.

"We have committed substantial capital to Hyperscale Data because we believe in the value of what it owns and the opportunities ahead," said Mr. Ault, Chief Executive Officer of Ault & Company and Executive Chairman of Hyperscale Data. "The Michigan campus has an executed customer agreement, significant capital invested and the potential to expand. Management believes that the campus could support a valuation of $750 million to $1.25 billion. Beyond Michigan, Hyperscale Data has established operating businesses and other strategic assets. As its largest stockholder, Ault & Company, together with its affiliates, is focused on supporting Hyperscale in the work needed to develop these assets and demonstrate their value over time."

Ault & Company expects to continue evaluating additional investments in Hyperscale Data, including its right to purchase up to an additional $96 million of series H convertible preferred stock, subject to market conditions, applicable securities laws and other considerations. This press release is for informational purposes only and shall not constitute an offer to buy or sell common stock or any other securities.

About Ault & Company, Inc.

Ault & Company, Inc. is a private holding company founded and controlled by Milton "Todd" Ault III. Ault & Company invests in public and private businesses across a variety of industries and seeks to create long-term value through active ownership, capital allocation and strategic development.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable federal securities laws. These forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "believes," "plans," "anticipates," "projects," "estimates," "expects," "intends," "strategy," "future," "opportunity," "may," "will," "should," "could," "potential," or similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties.

These forward-looking statements include, among other matters, statements regarding the potential value of Hyperscale Data and its assets, the Michigan AI data center campus, expected revenue and cash flow under the MSA, potential expansion of the Michigan facility, future power capacity, management's valuation estimates, Hyperscale Data's financial guidance, future investments by Ault & Company and its affiliates and potential efforts to realize or unlock value from Hyperscale Data's businesses and assets.

Forward-looking statements are based upon current expectations, estimates and assumptions and are subject to significant risks and uncertainties. Actual results could differ materially from those expressed or implied by such statements.

The approximately $1.2 billion MSA revenue figure assumes that the initial 20 MW deployment continues throughout the maximum 20-year term. The potential greater than $3.0 billion figure assumes, among other matters, that the customer exercises its expansion right to 52 MW and that the expanded capacity remains in service throughout the applicable maximum term. There can be no assurance that such extensions or expansion will occur.

Similarly, the estimated valuation range by Hyperscale Data's management for the Michigan facility of approximately $750 million to $1.25 billion represents its current opinion based upon presently available information and does not constitute an independent appraisal, fairness opinion, offer to purchase or sell any asset, or assurance that a transaction could be completed at any particular valuation.

Development of additional capacity at the Michigan facility is subject to financing, regulatory approvals, engineering requirements, utility agreements, infrastructure availability, customer demand and numerous other conditions.

Readers should review Hyperscale Data's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and the risk factors contained therein.

Forward-looking statements speak only as of the date they are made, and Ault & Company undertakes no obligation to update any of them publicly in light of new information or future events. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors.

SOURCE Ault & Company

Share this article

Marine Security Project to Be the First Tenant, Advancing the Company's Advanced Manufacturing Strategy in the UAE

UMM AL QUWAIN, UAE, Sept. 25, 2026 /PRNewswire/ -- Robo.ai Inc. (Nasdaq: AIIO) ("Robo.ai" or the "Company") today announced that a groundbreaking ceremony was held in Umm Al Quwain for Phase I of the ALIF Holding Group Industrial Park (the "Industrial Park"). The first of the Industrial Park's three planned phases will have a designed gross floor area of approximately 8,845 square meters and is expected to involve the refurbishment of existing factory premises to provide local integration and manufacturing capabilities for ALIF Holding's industrial projects. The site is intended to be held by a majority-owned subsidiary of ALIF Holding whose registration in Umm Al Quwain is in progress; the related transfer procedures are underway and subject to approval by the competent authorities.

The Phase I groundbreaking marks an important step in ALIF Holding's efforts to bring its projects into operation through the Industrial Park and establish a local industrial platform. For Robo.ai, the Industrial Park is an important part of its advanced manufacturing strategy. It will support the industrial application of relevant technologies and products in the UAE, facilitate commercialization with government, critical infrastructure and industrial customers, and underpin the development of the Company's intelligent infrastructure business.

Robo.ai previously announced plans to establish Alif Maritec, focused on marine security and intelligent maritime infrastructure. It is expected to be the first majority-owned subsidiary project to move into Phase I following refurbishment and operational readiness. Its proposed portfolio focuses on three areas:

Marine oil spill emergency response. The proposed system would connect spill detection, containment and recovery with water-quality verification. It is intended to link the main stages of marine pollution response, from identifying a spill and limiting its spread to recovering spilled material and checking water conditions, supporting coordinated emergency operations.

Land border security. For desert border protection, the planned solution would combine physical barriers, field sensors and unified command. By connecting on-site protection and detection with early warning and response coordination, it is intended to help operational teams understand conditions along the protected boundary and organize responses.

AI-enabled defense and intelligent monitoring. The proposed portfolio includes AI-enabled defense systems and a smart monitoring platform for critical infrastructure protection. The platform would use AI analytics and sensor data fusion to bring multiple sources of information into a real-time view of on-site conditions, supporting centralized command, assessment and coordinated response.

Phase I is intended to provide facilities for local manufacturing of these proposed products and for the integration of equipment and software systems, connecting development of the Industrial Park with specific project needs. Other ALIF Holding projects would be accommodated as business needs evolve.

The groundbreaking ceremony was attended by H.E. Dr. Ahmed Naser Al-Raisi, Chairman of ALIF Holding, together with Sheikh Ali bin Abdulrahman Al Nuaimi, a member of the ruling family of the Emirate of Ajman, and Sheikh Saqr bin Saud Al Mualla and Sheikh Al Mualla bin Ahmed Al Mualla, members of the ruling family of the Emirate of Umm Al Quwain. The attending guests spoke highly of ALIF Holding's industrial development plans and progress.

The ALIF Holding Group Industrial Park is planned to be developed in three phases. Phase I will use and refurbish existing factory premises to accommodate near-term projects; Phase II will involve the construction of new factory facilities to expand manufacturing capacity; and Phase III will provide reserve space for future projects and business expansion. This phased approach is designed to align facility development with business needs while balancing near-term plan with long-term growth. ALIF Holding aims to have at least three project companies establish operations in the Industrial Park by the end of 2026, subject to the availability and readiness of suitable premises and progress of each project.

"This project marks a new beginning for ALIF in the industrial sector," said Dr. Jasem Al Mansoori Chief Executive Officer of ALIF Holding. "Our goal is to combine advanced technologies with local manufacturing and build businesses that create long-term value for the UAE while serving international markets."

The Phase I refurbishment, the establishment of project companies within the Industrial Park and the commencement of commercial production will proceed in stages as the relevant conditions are met. The timing of each step will depend on the progress of the relevant works, completion of necessary company formation and approval procedures, availability of funding, and operational readiness.

About ALIF Holding

ALIF Holding is Robo.ai's Abu Dhabi-based industrial group, focused on intelligent software, intelligent equipment and the development of local industrial capabilities. Through international technology collaboration and local integration, it aims to develop intelligent systems and products for governments, critical infrastructure and industrial customers.

About Robo.ai Inc.

Robo.ai Inc. (Nasdaq: AIIO), headquartered in Dubai, United Arab Emirates, is a Nasdaq-listed technology group building intelligent infrastructure across four platforms: artificial intelligence; robotics and smart mobility; advanced manufacturing; and digital assets and capital. Its industrial group, ALIF Holding, is dedicated to building intelligent industries through the development, integration and manufacturing of AI systems, serving government, public sector and mission-critical domains. Through its majority-owned subsidiary Neurovia AI, the Company develops AI software and visual data infrastructure. Quantum Core Capital ("QC Capital"), its AI-powered deep-tech holding and venture-building platform, incubates, invests in and operates businesses across artificial intelligence, robotics, digital infrastructure and the next-generation digital economy.

Forward-Looking Statements

This press release contains statements that may constitute "forward-looking statements" pursuant to the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These include statements regarding the three-phase development plan and reserve space for the ALIF Holding Group Industrial Park; the proposed site holding and transfer arrangements; the target for at least three project companies to establish an on-site presence in the Industrial Park by the end of 2026; Phase I refurbishment and occupancy; subsequent phased development; the proposed establishment of Alif Maritec; planned products, solutions and their intended uses; local manufacturing capabilities; and expected strategic benefits. These statements may be identified by terms such as "plans," "targets," "expects," "intends," "aims," "will," "future" and similar expressions. Forward-looking statements involve inherent risks and uncertainties and are not guarantees of future results. Factors that could cause actual results to differ materially include the ability to secure and maintain necessary site rights, complete construction or refurbishment, obtain funding, establish project companies and recruit personnel; the availability of required licenses, permits and regulatory or other approvals; technology development, integration, validation and commercialization; Robo.ai's financial condition and results of operations, limited operating history in its current business, and ability to generate positive cash flow and profits; market demand, competition, operational, legal and economic conditions; and changes in government incentives, subsidies or other policies. Further information regarding these and other risks is included in Robo.ai's filings with the U.S. Securities and Exchange Commission, including its annual reports on Form 20-F and reports on Form 6-K. All information provided in this press release is as of its date. Robo.ai does not undertake any obligation to update any forward-looking statement, except as required by applicable law. This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities and should not be construed as an endorsement by any government or government agency.

Media Contacts

ALIF Holding Corporate Communications

Email: [email protected]

Website: www.alifholding.ai

Robo.ai Inc. Corporate Communications

Email: [email protected]

Website: www.roboai.group

SOURCE Robo.ai Inc.

Share this article

DELRAY BEACH, Fla., Sept. 25, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the plant growth regulator market is estimated at USD 3.72 billion in 2026 and is projected to reach USD 5.33 billion by 2031, at a CAGR of 7.4% from 2026 to 2031.

Plant Growth Regulators Market Size & Forecast

- Market Size Available for Years: 2021–2031

- 2026 Market Size: USD 3.72 billion

- 2031 Projected Market Size: USD 5.33 billion

- CAGR (2026–2031): 7.4%

Plant Growth Regulators Market Trends & Insights:

- The plant growth regulator market is expanding rapidly due to rising demand for higher crop productivity, quality, and efficient growth management. Increasing cultivation of high-value crops, limited arable land, and the shift toward precision and sustainable farming practices are driving adoption. Advancements in formulations and growing acceptance of bio-based regulators further support market growth, making plant growth regulators an integral part of modern agricultural systems.

- The Asia Pacific plant growth regulator market will register the highest CAGR of 8.8% during 2026-2031.

- By type, the cytokinins segment is expected to dominate the market.

- By function, the plant growth inhibitors segment is expected to register a significant CAGR of 8.3%.

- By formulation, the wettable powder segment is expected to register a market share of 17.3% in 2031.

- By crop type, the cereals & grains segment is expected to dominate the market.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=94580110

Demand for plant growth regulators worldwide is growing rapidly, driven by the increasing emphasis on sustainable agriculture practices like organic farming, which in turn increases demand for plant growth regulators that boost plant growth with low externalities in line with sustainable principles. Technological advancements in agriculture also support the market, driving better formulations and product development to improve the efficacy of plant growth regulators. Awareness of the advantages of plant growth regulators, the growing agricultural industry, and government initiatives boosting agricultural development have strengthened demand in this market. These push factors contribute to the global growth of the plant growth regulator market.

The ethylene segment holds a significant market share in the type segment of the plant growth regulator market.

Ethylene holds a significant share in the type segment of the plant growth regulator market because it regulates key physiological processes in crops, such as fruit ripening, flowering, leaf abscission, and stress response. Ethylene is highly versatile for horticultural and field crops, making it important for increasing yield and quality. Key examples include ethylene-releasing compounds such as ethephon, used to synchronize flowering, accelerate fruit ripening, and improve harvesting in major crops like tomatoes, bananas, apples, and cotton. Ethylene-based PGRs are therefore acceptable, given the growing demand for high-value fruits and vegetables; hence, ripening precision and uniformity are crucial prerequisites for market specifications and export regulations. Still, innovations in controlled-release and environmentally friendly ethylene formulations enable high efficacy in minimizing losses, strengthening the dominance of ethylene PGRs. These factors help keep ethylene in a leading position in the global plant growth regulator market.

In the formulation segment, solutions are growing at a significant rate in the plant growth regulator market.

Solutions hold a significant share in the formulations segment of the plant growth regulator market, driven by their ease of application, uniform coverage, and rapid absorption into crops. Liquid solutions enable accurate dosage control and can be used with existing spray equipment, making them suitable for large-scale agricultural operations as well as high-value horticultural crops. Through these formulations, active ingredients can be quickly translocated within the plant, causing rapid physiological responses such as enhanced growth, flowering, or fruit set, and increasing crop stress tolerance. Solution-based PGRs are also versatile and can be applied via foliar sprays, soil drenching, and fertigation systems, broadening their use across crop types, including fruits, vegetables, cereals, and ornamentals. Advances in shade stabilizers and the production of water-soluble formulations also extend shelf life, increase efficacy, and improve environmental safety, further boosting this category's market preference. These attributes have established this formulation as the dominant segment in the global plant growth regulator market.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=94580110

Based on region, Europe holds a significant share in the plant growth regulator market.

Europe occupies a significant share in the plant growth regulator market, boasting some of the advanced agri-tech practices and high levels of technologic application in horticulture, have the largest share in the global plant growth regulators market for certain very high-economic-value crops-fruit, vegetables, and cereals. In these countries, especially Germany, France, Italy, and Spain, horticulture and commercial farming systems are well defined, and precision crop management is central to sustaining yields and quality. The regulations in Europe, which enforce an innovative orientation to PGR solutions, are now targeting bio-based and environmentally safe product formulations, contributing further to the market growth. Increased awareness of crop stress management, along with investments in research and development, has led to advanced PGR products with higher efficacy and safety profiles. These factors, along with rising demand for uniform fruit ripening, flowering control, and faster harvest efficiency, position Europe as a key PGR market.

Top Companies in the Plant Growth Regulators Market

The key companies operating in the plant growth regulator market include BASF SE (Germany), Corteva Agriscience (United States), Syngenta Group (Switzerland), FMC Corporation (United States), Nufarm (Australia), Bayer AG (Germany), Tata Chemicals Ltd. (India), UPL (India), Sumitomo Chemical Co., Ltd. (Japan), Nippon Soda Co., Ltd. (Japan), SIPCAM OXON S.p.A. (Italy), De Sangosse (France), Dhanuka Agritech Ltd. (India), Sichuan Guoguang Agrochemical Co., Ltd. (China), and Zagro (Singapore).

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=94580110

Investment Funding Context

The plant growth regulator market is attracting increasing investment as demand rises for crop productivity, yield optimization, and efficient plant-growth management solutions. Investment activity is increasingly focused on biostimulants, hormone-based formulations, microbial and biological growth regulators, and advanced formulation technologies. Companies and technology developers are directing capital toward improving product efficacy, application efficiency, formulation stability, and commercialization capabilities. Funding and strategic investments in these areas reflect growing interest in technologies that regulate plant growth, improve crop development, enhance stress tolerance, and optimize resource utilization. The expansion of intensive and sustainable agriculture, together with the need to improve crop productivity under changing climatic conditions, is expected to continue creating investment opportunities across the plant growth regulators value chain.

Revenue Shift Context

The plant growth regulator market is estimated at USD 3.72 billion in 2026 and is projected to reach USD 5.33 billion by 2031, registering a CAGR of 7.4% during 2026–2031. Revenue growth is supported by increasing adoption of auxins, gibberellins, cytokinins, ethylene regulators, abscisic acid, and other plant growth-regulating solutions across commercial agriculture. Demand is being driven by the need to improve crop yield and quality, regulate flowering and fruit development, enhance stress tolerance, and optimize crop production cycles. Fruits & vegetables represent a significant application area because of their high-value production and sensitivity to growth and quality parameters, while Asia Pacific accounts for a significant share of market demand due to its large agricultural base and increasing use of crop productivity-enhancing inputs. Europe is also expected to growth strongly as sustainable crop production, resource-use efficiency, and advanced crop-management practices gain importance.

Mergers and Acquisitions

Mergers and acquisitions in the plant growth regulator market are increasingly focused on expanding crop-management portfolios, strengthening capabilities in plant-growth regulation and biological crop inputs, and gaining access to innovative formulations and technologies. Companies are seeking to complement conventional crop-protection and crop-input offerings with solutions that regulate flowering, fruit development, plant architecture, crop maturity, and stress responses. Acquisitions and strategic investments also enable companies to expand geographic presence, strengthen distribution networks, accelerate product commercialization, and enhance R&D capabilities. Growing demand for higher crop productivity, improved crop quality, controlled plant development, and efficient agricultural input use is expected to support further consolidation. M&A activity is likely to remain concentrated across auxins, gibberellins, cytokinins, ethylene regulators, abscisic acid, and other advanced plant-growth regulation technologies.

PLANT GROWTH REGULATOR MARKET: MERGERS AND ACQUISITIONS, MARCH 2025–JULY 2026

Company Revenue Share Details

The plant growth regulator market is moderately competitive, with the top five companies—Syngenta Group, BASF SE, Bayer AG, Corteva, and Sumitomo Chemical Co.